Healthcare · NYSE/NASDAQ: ORIC
ORIC
Biotechnology
Market Cap $0.87B
Verdict: Weak
Quality Scores
Multi-Bagger
45/100
Compounder Quality
30/100
Management Credibility
70/100
Governance
82/100
Cash Flow Quality
35/100
AI Summary
ORIC Pharmaceuticals is a clinical-stage precision oncology company focused on overcoming resistance mechanisms in cancer. The firm relies on a diverse pipeline, specifically targeting androgen receptor (AR) and glucocorticoid receptor (GR) pathways. Since its 2020 IPO, ORIC has maintained a robust cash position but remains a pre-revenue venture typical of the biotech sector. Its investment thesis hinges entirely on clinical trial outcomes rather than current financial performance. The company’s strategic partnerships, such as those with Pfizer, provide external validation of its research…
Top Opportunities
- Robust cash position relative to current market cap
- Strategic partnership with Pfizer (ORIC-944)
- Focus on overcoming resistance in cancer (high unmet need)
Top Risks
- No steady revenue stream currently
- Consistently high annual cash burn (> $90M)
- Significant reliance on future equity raises
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.